Gemcitabine monotherapy
Checked 2026-09-09
Frail patients or adjuvant when combinations are not tolerated
One cycle
every 28 days × 6 · about 24 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Gemcitabine Nucleoside analogue (deoxycytidine) | 1,000 mg/m² | IV | D1, 8, 15 |
Cycles
6 (adjuvant); until progression
28-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine
Used in
Products
Source
Burris, JCO 1997 (7 weekly doses then 3 of 4 weeks); CONKO-001 adjuvant
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
mFOLFOX6
Adjuvant stage III colon (6 months) or metastatic colorectal and upper GI first line
every 14 days × 12
FOLFIRINOX
Metastatic pancreatic cancer, performance status 0-1
every 14 days × 12
mFOLFIRINOX (adjuvant)
Resected pancreatic cancer, fit patients, started within 12 weeks of surgery
every 14 days × 12
Gemcitabine + nab-paclitaxel
Metastatic pancreatic cancer first line; adjuvant option when FOLFIRINOX is not tolerated
every 28 days
NALIRIFOX
Metastatic pancreatic cancer first line
every 14 days
Gemcitabine + cisplatin
Advanced biliary tract cancer first line (with durvalumab or pembrolizumab); cisplatin-eligible urothelial cancer
every 21 days × 8
Olaparib maintenance
Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum
every 28 days × 2